Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results
The revision follows the company’s performance in the third quarter, marked by the first positive GAAP net income and solid revenue execution.
Amicus Therapeutics Inc. (FOLD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 15,025,000 | $118,397,000 | -17% | 1.53% |
| 2. | Millennium Management Israel Englander | 11,809,796 | $93,061,192 | +60% | 0.04% |
| 3. | Vestal Point Capital Ryan Wilder | 9,750,000 | $76,830,000 | -19% | 3.47% |
| 4. | Citadel Investment Group Ken Griffin | 8,250,140 | $65,011,103 | +39% | 0.01% |
| 5. | Point72 Asset Management Steve Cohen | 7,156,557 | $56,393,679 | +119% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | $15,735.00 | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | $14,346.00 | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | $17,115.00 | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | $13,920.00 | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | $13,861.20 | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.16 | 76,158 | $773,658.66 | 439,318 | 2025-11-24 | Filing | |
| $10.10 | 25,643 | $258,932.76 | 296,975 | 2025-11-24 | Filing | |
| $10.04 | 14,587 | $146,522.04 | 1,137,282 | 2025-11-24 | Filing | |
| $10.00 | 23,621 | $236,210.00 | 507,710 | 2025-11-26 | Filing | |
| $10.00 | 36,000 | $360,000.00 | 507,710 | 2025-11-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,534,029 | $232,728,149 | 0% | |
| 2. | 28,628,829 | $225,595,173 | 0.04% | |
| 3. | 25,848,965 | $203,689,844 | 0% | |
| 4. | 15,749,240 | $124,104,011 | 0.32% | |
| 5. | 11,562,939 | $91,115,959 | 0% |
News See All
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Third Quarter 2025 Financial Results Conference Call and webcast.
What Does Wall Street Think About Amicus Therapeutics (FOLD)?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Amicus Therapeutics, Inc. (FOLD) Expands Pipeline With Rare Kidney Disease Drug
Amicus Therapeutics, Inc. (NASDAQ:FOLD) tops our list for being one of the best biotech stocks. It develops therapies for rare diseases, including Fabry disease and late-onset Pompe disease.
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Second Quarter 2025 Financial Results Conference Call and webcast.
Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best strong buy stocks to buy under $10.
10 Best Strong Buy Stocks to Buy Under $10
He stated that there are a couple of factors behind this, including an improvement in trade, as more trade deals continue to be announced.